Adherex entered into a dual drug development deal with GSK. The deal brings in a profit of up to US$220 M to Adherex and allows GSK to retain its options pertaining to Adherex’s eniluracil and Exherin(TM). Getting a huge pharma player like GSK on its side is a remarkable achievement for Adherex. This partnership has helped Adherex to carry on with the development of its proprietary oncology pipeline.